Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark
Justin Taylor, Michael Haddadin, Vivek Upadhyay, et al.
Blood (2019) Vol. 134, Iss. 8, pp. 678-687
Open Access | Times Cited: 84

Showing 26-50 of 84 citing articles:

TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm
Hannah C. Beird, C. Cameron Yin, Joseph D. Khoury, et al.
Blood Advances (2023) Vol. 7, Iss. 10, pp. 2000-2003
Open Access | Times Cited: 8
Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm
Marlise R. Luskin, Andrew A. Lane
Haematologica (2023)
Open Access | Times Cited: 8
New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm
Xiang Zhang, Jiewen Sun, Min Yang, et al.
Critical Reviews in Oncology/Hematology (2020) Vol. 149, pp. 102928-102928
Closed Access | Times Cited: 19
Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?
Margaux Poussard, Fanny Angelot‐Delettre, Éric Deconinck
Cancers (2022) Vol. 14, Iss. 15, pp. 3767-3767
Open Access | Times Cited: 12
Minor introns impact on hematopoietic malignancies
Koutarou Nishimura, Wataru Saika, Daichi Inoue
Experimental Hematology (2024) Vol. 132, pp. 104173-104173
Closed Access | Times Cited: 2
Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View
Cosimo Di Raimondo, Flavia Lozzi, Pier Paolo Di Domenico, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7099-7099
Open Access | Times Cited: 2
Dysregulated minor intron splicing in cancer
Koutarou Nishimura, Hiromi Yamazaki, Weijia Zang, et al.
Cancer Science (2022) Vol. 113, Iss. 9, pp. 2934-2942
Open Access | Times Cited: 11
Genetics and Epigenetics in Neoplasms with Plasmacytoid Dendritic Cells
Florian Renosi, Mary Callanan, Christine Lefebvre
Cancers (2022) Vol. 14, Iss. 17, pp. 4132-4132
Open Access | Times Cited: 11
Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm – collected cases from a single center and case reports
Philipp Faustmann, Jan C. Schroeder, Lucas Mix, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm
Michael Haddadin, Justin Taylor
Hematology/Oncology Clinics of North America (2020) Vol. 34, Iss. 3, pp. 539-552
Closed Access | Times Cited: 15
Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm
Andrew A. Lane
Hematology/Oncology Clinics of North America (2020) Vol. 34, Iss. 3, pp. 589-600
Closed Access | Times Cited: 15
<p>Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data</p>
Guillaume Béziat, Loïc Ysebaert
OncoTargets and Therapy (2020) Vol. Volume 13, pp. 5199-5205
Open Access | Times Cited: 15
Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review.
Dima Abla, Miguel R. Abboud, Dolly Noun, et al.
Leukemia Research Reports (2022) Vol. 17, pp. 100313-100313
Open Access | Times Cited: 9
Incidence, prognostic factors, and survival outcomes in patients with blastic plasmacytoid dendritic cell neoplasm: A retrospective study in the Surveillance, Epidemiology, and End Results database
Xiao-Jing Lin, Li Wang, Qian Hu, et al.
European Journal Of Haematology (2023) Vol. 110, Iss. 6, pp. 743-753
Closed Access | Times Cited: 5
Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Minas P. Economides, David A. Rizzieri, Naveen Pemmaraju
Current Hematologic Malignancy Reports (2019) Vol. 14, Iss. 6, pp. 515-522
Closed Access | Times Cited: 13
Venetoclax in relapsed/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature
Nil Albiol, Silvana Novelli, Anna Mozos, et al.
Journal of Medical Case Reports (2021) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN)
James A. Davis, David A. Rizzieri, Andrew A. Lane, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2022) Vol. 63, Iss. 11, pp. 2757-2759
Closed Access | Times Cited: 8
Blastic Plasmacytoid Dendritic Cell Neoplasm
Jesse Hirner, John T. O’Malley, Nicole R. LeBoeuf
Hematology/Oncology Clinics of North America (2020) Vol. 34, Iss. 3, pp. 501-509
Closed Access | Times Cited: 11
Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm
Jason Nomburg, Susan Bullman, Sun Sook Chung, et al.
Blood Advances (2020) Vol. 4, Iss. 6, pp. 1006-1011
Open Access | Times Cited: 11
Dendritic Cell Leukemia: a Review
Nikolaos J. Tsagarakis, Georgios Paterakis
Current Oncology Reports (2020) Vol. 22, Iss. 6
Closed Access | Times Cited: 11
Targeting CD123 in BPDCN: an emerging field
Adam J. DiPippo, Nathaniel R. Wilson, Naveen Pemmaraju
Expert Review of Hematology (2021) Vol. 14, Iss. 11, pp. 993-1004
Closed Access | Times Cited: 10
Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm
Yumeng Zhang, Lubomir Sokol
Cancer Management and Research (2022) Vol. Volume 14, pp. 2107-2117
Open Access | Times Cited: 7
Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Naveen Pemmaraju, Éric Deconinck, Priyanka Mehta, et al.
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 24, Iss. 4, pp. e130-e137
Open Access | Times Cited: 4
Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations
Naveen Pemmaraju, Yazan F. Madanat, David A. Rizzieri, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024) Vol. 65, Iss. 5, pp. 548-559
Open Access | Times Cited: 1
Organ involvement in adults with BPDCN is associated with sun exposure history, TET2 and RAS mutations, and survival
Shai Shimony, Julia Keating, Christopher J. Fay, et al.
Blood Advances (2024) Vol. 8, Iss. 11, pp. 2803-2812
Open Access | Times Cited: 1

Scroll to top